by Richard Daverman, PhD
September 14, 2013 --Genor, a biologics company, may be sold to a strategic buyer soon and the suitor may be Walvax Biotech, which reportedly plans to IPO the company in the US; Sinopharm and China NT Pharma have earmarked $33 million of initial capital to build a cold-chain drug distribution company in Shanghai; CANbridge Life Sciences of Beijing secured China rights to a lung cancer drug from US-based Azaya Therapeutics; MicroConstants China, a Beijing area CRO, in-licensed the China rights to a liver cancer drug from Pertinax of Canada; Luqa Pharma will distribute more of Stratpharma’s dermatology products in China; Ironwood and AstraZeneca began a China Phase III clinical trial of linaclotide for IBS; Ventana, a Roche subsidiary, received China approval for a companion diagnostic to Pfizer’s Xalkori; BGI Tech Solutions will collaborate on a cancer genome/outcomes study with San Antonio hospitals; two domestic China drugmakers, Sino Biopharma and Gan & Lee, were charged with bribing China doctors to increase sales; ASLAN Pharma of Singapore was named one of the Red Herring Top 100 Asia Award 2013 winners; and DelMar Pharma and Guangxi Wuzhou Pharma have formed a China clinical advisory board to oversee China trials of their cancer treatment. More details….
Stock Symbols: (SHE: 300142) (HK: 1099) (HK: 1011) (NSDQ: IRWD) (NYSE: AZN) (SX: ROG) (NYSE: PFE) (HK: 1177) (OTCQB: DMPI)
Help employers find you! Check out all the jobs and post your resume.
